NewLink Genetics Corporation (NLNK) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research cut shares of NewLink Genetics Corporation (NASDAQ:NLNK) from a buy rating to a hold rating in a research note released on Wednesday.

According to Zacks, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. “

NLNK has been the subject of several other research reports. Jefferies Group LLC reduced their target price on shares of NewLink Genetics Corporation from $26.00 to $25.00 and set a buy rating for the company in a research note on Friday, November 3rd. ValuEngine lowered shares of NewLink Genetics Corporation from a sell rating to a strong sell rating in a research note on Tuesday, September 26th. Cantor Fitzgerald reiterated a buy rating and issued a $26.00 target price on shares of NewLink Genetics Corporation in a research note on Thursday, November 2nd. Stifel Nicolaus upped their target price on shares of NewLink Genetics Corporation from $25.00 to $29.00 and gave the stock a buy rating in a research note on Friday, November 3rd. Finally, Bank of America Corporation initiated coverage on shares of NewLink Genetics Corporation in a research note on Friday, October 13th. They issued a buy rating and a $22.00 target price for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $23.43.

Shares of NewLink Genetics Corporation (NLNK) traded up $0.15 during mid-day trading on Wednesday, reaching $9.02. 1,035,500 shares of the company’s stock were exchanged, compared to its average volume of 1,316,122. NewLink Genetics Corporation has a fifty-two week low of $5.90 and a fifty-two week high of $25.17.

COPYRIGHT VIOLATION WARNING: “NewLink Genetics Corporation (NLNK) Rating Lowered to Hold at Zacks Investment Research” was first published by Markets Daily and is the sole property of of Markets Daily. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.themarketsdaily.com/2017/11/12/newlink-genetics-corporation-nlnk-rating-lowered-to-hold-at-zacks-investment-research.html.

In related news, major shareholder Stine Seed Farm, Inc. purchased 780,487 shares of NewLink Genetics Corporation stock in a transaction that occurred on Friday, October 6th. The stock was bought at an average price of $10.25 per share, for a total transaction of $7,999,991.75. Following the completion of the transaction, the insider now owns 7,857,732 shares in the company, valued at $80,541,753. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 13.70% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Eqis Capital Management Inc. grew its position in NewLink Genetics Corporation by 0.6% during the second quarter. Eqis Capital Management Inc. now owns 32,999 shares of the biotechnology company’s stock valued at $243,000 after buying an additional 183 shares during the period. The Manufacturers Life Insurance Company grew its position in NewLink Genetics Corporation by 3.0% during the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock valued at $140,000 after buying an additional 556 shares during the period. Advisor Group Inc. grew its position in NewLink Genetics Corporation by 3.4% during the second quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 600 shares during the period. American International Group Inc. grew its position in NewLink Genetics Corporation by 7.1% during the first quarter. American International Group Inc. now owns 13,321 shares of the biotechnology company’s stock valued at $321,000 after buying an additional 880 shares during the period. Finally, Northwest Wealth Management LLC grew its position in NewLink Genetics Corporation by 3.1% during the second quarter. Northwest Wealth Management LLC now owns 58,022 shares of the biotechnology company’s stock valued at $426,000 after buying an additional 1,740 shares during the period. Institutional investors own 55.30% of the company’s stock.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Get a free copy of the Zacks research report on NewLink Genetics Corporation (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply